Search Results

You are looking at 91 - 94 of 94 items for :

  • "pain management" x
Clear All
Full access

Gary R. Hudes, Michael A. Carducci, Toni K. Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim A. Margolin, M. Dror Michaelson, Robert J. Motzer, Roberto Pili, Susan Roethke and Sandy Srinivas

lidocaine 2%, may also be used for pain management. Table 4 Grades of Dermatologic Toxicities Using the Common Terminology Criteria for Adverse Events Significant debate exists regarding how best to grade the various dermatologic toxicities. A standard

Full access

should use nonpharmacologic interventions, including physical, cognitive, and spiritual pain management tools. Effective 2018, The Joint Commission will require nonpharmacologic pain treatment as a performance element for accredited healthcare facilities

Full access

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi Kumar, Georgia Litsas, Rana McKay, Donald A. Podoloff, Sandy Srinivas and Catherine H. Van Poznak

efficacy of percutaneous vertebroplasty for vertebral metastases associated with solid malignancies . Eur J Cancer 2009 ; 45 : 1597 – 1602 . 329 Saliou G Kocheida el M Lehmann P . Percutaneous vertebroplasty for pain management in malignant

Full access

Joseph C. Alvarnas, Patrick A. Brown, Patricia Aoun, Karen Kuhn Ballen, Naresh Bellam, William Blum, Michael W. Boyer, Hetty E. Carraway, Peter F. Coccia, Steven E. Coutre, Jennifer Cultrera, Lloyd E. Damon, Daniel J. DeAngelo, Dan Douer, Haydar Frangoul, Olga Frankfurt, Salil Goorha, Michael M. Millenson, Susan O'Brien, Stephen H. Petersdorf, Arati V. Rao, Stephanie Terezakis, Geoffrey Uy, Meir Wetzler, Andrew D. Zelenetz, Maoko Naganuma and Kristina M. Gregory

, pain management, prevention and management of infectious complications, and prophylaxis for TLS. In addition, both short- and long-term consequences of potential toxicities associated with specific agents used in ALL regimens should be considered, such